IMR Press / FBS / Volume 8 / Issue 1 / DOI: 10.2741/S445

Frontiers in Bioscience-Scholar (FBS) is published by IMR Press from Volume 13 Issue 1 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.


Elevated XPO6 expression as a potential prognostic biomarker for prostate cancer recurrence

Show Less
1 Department of Experimental Therapeutics, BC Cancer Agency, Vancouver, BC, Canada, V5Z 1L3
2 Vancouver Prostate Centre, Vancouver, BC, Canada, V6H 3Z6
3 Department of Urologic Sciences, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada, V5Z 1M9
4 Interdisciplinary Oncology Program, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada, V5Z 1L3

*Author to whom correspondence should be addressed.

Academic Editor: Francesco Crea

Front. Biosci. (Schol Ed) 2016, 8(1), 44–55;
Published: 1 January 2016
(This article belongs to the Special Issue Next-generation cancer biomarkers)

Recurrence of localized prostate cancer following treatment can lead to lethal metastatic castration-resistant prostate cancer. Although numerous studies aimed at developing biomarkers for predicting recurrence of localized prostate cancer are promising, they have not yet led to useful applications. Dysregulation of exportins (XPOs, nucleocytoplasmic transporters) associated with subcellular mislocalization of proteins has been reported for various human cancers. However, most of the XPOs have not been studied in prostate cancer. In this study, we are the first to examine whether changes in expression of XPOs could be used as potential biomarkers for recurrence of localized prostate cancer. Using the oncomine database, gene expressions of 7 known XPOs by 1128 patient samples, obtained from 16 independent prostate cancer patient cohorts, were analyzed. Relatively highly elevated expression of XPO6 (compared to prostate cancer tissue) was found to be significantly associated with poor patient prognosis, in particular, with rapid recurrence in a clinical “low risk” group. As such, expression of XPO6 may be a potential prognostic biomarker for predicting prostate cancer recurrence.

Prostate Cancer
Prognostic Biomarker
Cancer Recurrence
Exportin 6
Back to top